{"id":72426,"date":"2026-08-13T11:54:50","date_gmt":"2026-08-13T03:54:50","guid":{"rendered":"https:\/\/flcube.com\/?p=72426"},"modified":"2026-08-13T11:54:51","modified_gmt":"2026-08-13T03:54:51","slug":"akesos-ivonescimab-wins-nmpa-approval-for-first-line-advanced-squamous-non-small-cell-lung-cancer-in-combination-with-chemotherapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72426","title":{"rendered":"Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy"},"content":{"rendered":"\n

Akeso Biopharma<\/strong> (HKG: 9926<\/a>) announced that the National Medical Products Administration (NMPA)<\/strong> of China has approved the supplemental New Drug Application (sNDA)<\/strong> for ivonescimab<\/strong> \u2014 its first-in-class Immuno-Oncology 2.0 cornerstone drug<\/strong> \u2014 in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Akeso Biopharma (HKG: 9926)<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Supplemental New Drug Application (sNDA)<\/td><\/tr>
Drug<\/strong><\/td>Ivonescimab (first-in-class IO 2.0 bispecific)<\/td><\/tr>
Indication<\/strong><\/td>First-line advanced squamous NSCLC, in combination with chemotherapy<\/td><\/tr>
Approval Date<\/strong><\/td>12 Aug 2026<\/td><\/tr>
Significance<\/strong><\/td>3rd approved lung cancer indication for ivonescimab<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Redefining the Standard of Care<\/h2>\n\n\n\n